CDSCO India Equivalent to US FDA Approves Photocil for Sale – Jupiter Wellness (NASDAQ:JUPW) – Benzinga


Jupiter Wellness, Inc. JUPW, a wellness company focused on hair loss, eczema, burns, and sexual wellness announced that its Photocil product (branded as PhotoFirst in India) has been approved by the Drugs Controller General of India (CDSCO) for sale in India. The CDSCO is India’s equivalent of the FDA in the United States.
Photocil is a topical product that filters UV rays from the sun to allow only the therapeutic UV spectrum to penetrate the skin. It is used for the treatment of psoriasis and vitiligo.
On the heels of this announcement, members of the Jupiter Wellness scientific team are traveling to India to meet with partners at ErisOaknet Healthcare, an Indian pharmaceutical company, and to present at an upcoming International Speaker Program in Mumbai on November 12, 2022. 
The International Speaker Program is focused on redefining phototherapy in autoimmune diseases of the skin. The event will feature presentations from Jupiter Wellness’s Dr. Glynn Wilson, Chief Scientific Officer, and Prof. Dr. Andy Goren, the inventor of Photocil.
In Q2 2022, Sanpellegrino Cosmetics Pvt Ltd & Cosmofix Technovation Pvt Ltd signed a licensing agreement with Jupiter Wellness for the distribution and sales of the Company’s Photocil product to 31 countries including the Indian market. The commercial launch of which is expected to begin in Q1 2023.
Dr. Glynn Wilson, Chief Scientific Officer at Jupiter Wellness, said, “We’re excited to visit India, home to some of our current licensing partners, and a region of great interest to us as we continue to expand our reach into international markets.”
Image sourced from Shutterstock
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

source


Leave a Reply

Your email address will not be published.